Prime, shock, and kill: Priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size

Journal of Virology

Volumn 90, Issue 8, 2016, Pages 4032-4048

  Cummins, Nathan W ^a   Sainski, Amy M ^a   Dai, Haiming ^a   Natesampillai, Sekar ^a   Pang, Yuan Ping ^a   Bren, Gary D ^a   De Araujo Correia, Maria Cristina Miranda ^a   Sampath, Rahul ^a   Rizza, Stacey A ^a   O'Brien, Daniel ^a   Yao, Joseph D ^a   Kaufmann, Scott H ^a   Badley, Andrew D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROCASPASE 8; PROTEIN BAK; PROTEIN BCL 2; VENETOCLAX; VIRUS DNA; BAK1 PROTEIN, HUMAN; CASPASE 8; CASPASE INHIBITOR; FUSED HETEROCYCLIC RINGS; PEPTIDE FRAGMENT; PROTEIN BINDING; SULFONAMIDE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPRECIPITATION; JURKAT CELL LINE; MOLECULAR MODEL; NEXT GENERATION SEQUENCING; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; VIRUS REACTIVATION; VIRUS REPLICATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL DEATH; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIRUS ACTIVATION; VIRUS LOAD;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CASPASE 8; CASPASE INHIBITORS; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; HEK293 CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; JURKAT CELLS; PEPTIDE FRAGMENTS; PROTEIN BINDING; SULFONAMIDES; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84963878365     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03179-15     Document Type: Article

References (97)

1. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487:482-485. http://dx.doi.org/10.1038/nature11286.
2. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sekaly RP, Lewin SR. 2014. Activation of HIV transcription with short-course vorinostat in HIVinfected patients on suppressive antiretroviral therapy. PLoS Pathog 10: e1004473. http://dx.doi.org/10.1371/journal.ppat.1004473.
3. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Løstergaard-Søgaard OS. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1:e13-e21. http://dx.doi.org/10.1016/S2352-3018(14)70014-1.
4. Sogaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, Schleimann MH, Denton PW, Hey-Cunningham WJ, Koelsch KK, Pantaleo G, Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N, Rasmussen TA, Ostergaard L, Tolstrup M. 2015. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog 11:e1005142. http://dx.doi.org/10.1371/journal.ppat.1005142.
5. Cummins NW, Badley AD. 2010. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Dis 1:e99. http://dx.doi.org/10.1038/cddis.2010.77.
6. Solis M, Nakhaei P, Jalalirad M, Lacoste J, Douville R, Arguello M, Zhao T, Laughrea M, Wainberg MA, Hiscott J. 2011. RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol 85:1224-1236. http://dx.doi.org/10.1128/JVI.01635-10.
7. Jiang F, Ramanathan A, Miller MT, Tang GQ, Gale M, Jr, Patel SS, Marcotrigiano J. 2011. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 479:423-427. http://dx.doi.org/10.1038/nature10537.
8. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Munoz-Arias I, Greene WC. 2014. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505:509-514. http://dx.doi.org/10.1038/nature12940.
9. Monroe KM, Yang Z, Johnson JR, Geng X, Doitsh G, Krogan NJ, Greene WC. 2014. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 343:428-432. http://dx.doi.org/10.1126/science.1243640.
10. Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. 2013. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 498:376-379. http://dx.doi.org/10.1038/nature12274.
11. Kaplan AH, Swanstrom R. 1991. The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. Biomed Biochim Acta 50:647-653.
12. Kaplan AH, Manchester M, Swanstrom R. 1994. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol 68:6782-6786.
13. Nie Z, Phenix BN, Lum JJ, Alam A, Lynch DH, Beckett B, Krammer PH, Sekaly RP, Badley AD. 2002. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell Death Differ 9:1172-1184. http://dx.doi.org/10.1038/sj.cdd.4401094.
14. Nie Z, Bren GD, Vlahakis SR, Schimnich AA, Brenchley JM, Trushin SA, Warren S, Schnepple DJ, Kovacs CM, Loutfy MR, Douek DC, Badley AD. 2007. Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo. J Virol 81:6947-6956. http://dx.doi.org/10.1128/JVI.02798-06.
15. Nie Z, Bren GD, Rizza SA, Badley AD. 2008. HIV protease cleavage of procaspase 8 is necessary for death of HIV-infected cells. Open Virol J 2:1-7. http://dx.doi.org/10.2174/1874357900802010001.
16. Sainski AM, Natesampillai S, Cummins NW, Bren GD, Taylor J, Saenz DT, Poeschla EM, Badley AD. 2011. The HIV-1-specific protein Casp8p41 induces death of infected cells through Bax/Bak. J Virol 85: 7965-7975. http://dx.doi.org/10.1128/JVI.02515-10.
17. Sainski AM, Dai H, Natesampillai S, Pang YP, Bren GD, Cummins NW, Correia C, Meng XW, Tarara JE, Ramirez-Alvarado M, Katzmann DJ, Ochsenbauer C, Kappes JC, Kaufmann SH, Badley AD. 2014. Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. J Cell Biol 207:159. http://dx.doi.org/10.1083/jcb.20140505109252014c.
18. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36:491-501. http://dx.doi.org/10.1016/j.immuni.2012.01.014.
19. Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, Zubair AC, Vuk-Pavlovic S. 2006. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 46: 2083-2089. http://dx.doi.org/10.1111/j.1537-2995.2006.01033.x.
20. Bren GD, Whitman J, Cummins N, Shepard B, Rizza SA, Trushin SA, Badley AD. 2008. Infected cell killing by HIV-1 protease promotes NF-κB dependent HIV-1 replication. PLoS One 3:e2112. http://dx.doi.org/10.1371/journal.pone.0002112.
21. Smith AJ, Dai H, Correia C, Takahashi R, Lee SH, Schmitz I, Kaufmann SH. 2011. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 286:17682-17692. http://dx.doi.org/10.1074/jbc.M110.189092.
22. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749-759. http://dx.doi.org/10.1084/jem.20040874.
23. Cummins NW, Neuhaus J, Sainski AM, Strausbauch MA, Wettstein PJ, Lewin SR, Plana M, Rizza SA, Temesgen Z, Touloumi G, Freiberg M, Neaton J, Badley AD. 2014. Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued pro-duction of Casp8p41. AIDS Res Hum Retroviruses 30:476-479. http://dx.doi.org/10.1089/aid.2013.0243.
24. Liszewski MK, Yu JJ, O'Doherty U. 2009. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods 47:254-260. http://dx.doi.org/10.1016/j.ymeth.2009.01.002.
25. Anders S, Huber W. 2010. Differential expression analysis for sequence count data. Genome Biol 11:R106. http://dx.doi.org/10.1186/gb-2010-11-10-r106.
26. Diez J, Walter D, Munoz-Pinedo C, Gabaldon T. 2010. DeathBase: a database on structure, evolution and function of proteins involved in apoptosis and other forms of cell death. Cell Death Differ 17:735-736. http://dx.doi.org/10.1038/cdd.2009.215.
27. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:25-29.
28. Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30. http://dx.doi.org/10.1093/nar/28.1.27.
29. Pang YP. 2014. Low-mass molecular dynamics simulation: a simple and generic technique to enhance configurational sampling. Biochem Biophys Res Commun 452:588-592. http://dx.doi.org/10.1016/j.bbrc.2014.08.119.
30. Pang YP. 2015. Low-mass molecular dynamics simulation for configurational sampling enhancement: more evidence and theoretical explanation. Biochem Biophys Rep 4:126-133.
31. Pang YP. 2015. At least 10% shorter C-H bonds in cryogenic protein crystal structures than in current AMBER forcefields. Biochem Biophys Res Commun 458:352-355. http://dx.doi.org/10.1016/j.bbrc.2015.01.115.
32. Pang YP. 2015. Use of 1-4 interaction scaling factors to control the conformational equilibrium between alpha-helix and beta-strand. Biochem Biophys Res Commun 457:183-186. http://dx.doi.org/10.1016/j.bbrc.2014.12.084.
33. Berendsen HJC, van Gunsteren PJWF, Di Nola A, Haak JR. 1984. Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690. http://dx.doi.org/10.1063/1.448118.
34. Darden TA, YD & Pedersen LG. 1993. Particle mesh Ewald: An N log(N) method for Ewald sums in large systems. J Chem Phys 98:10089-10092. http://dx.doi.org/10.1063/1.464397.
35. Shao J, Thompson TSN, Cheatham III TE. 2007. Clustering molecular dynamics trajectories: 1. Characterizing the performance of different clustering algorithms. J Chem Theory Comput 3:2312-2334.
36. + memory T cells. Nat Commun 5:5407. http://dx.doi.org/10.1038/ncomms6407.
37. Deeks SG. 2012. HIV: Shock and kill. Nature 487:439-440. http://dx.doi.org/10.1038/487439a.
38. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, Kuruppu J, Yazdani J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. 2004. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 78:1160-1168. http://dx.doi.org/10.1128/JVI.78.3.1160-1168.2004.
39. Cummins NW, Jiang W, McGinty J, Bren GD, Bosch RJ, Landay A, Deeks SG, Martin JN, Douek D, Lederman MM, Brenchley J, Badley AD. 2010. Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis 202:386-391. http://dx.doi.org/10.1086/653705.
40. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900. http://dx.doi.org/10.1038/nm.1972.
41. + T cells in healthy humans. J Exp Med 200:255-260. http://dx.doi.org/10.1084/jem.20040341.
42. + T cells during HIV infection. Nat Med 14:266-274. http://dx.doi.org/10.1038/nm1728.
43. Dai H, Meng XW, Lee SH, Schneider PA, Kaufmann SH. 2009. Contextdependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J Biol Chem 284:18311-18322. http://dx.doi.org/10.1074/jbc.M109.004770.
44. + stem cell memory T cells. Clin Immunol 159: 107-117. http://dx.doi.org/10.1016/j.clim.2015.04.010.
45. Czabotar PE, Lessene G, Strasser A, Adams JM. 2014. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15:49-63. http://dx.doi.org/10.1038/nrm3722.
46. Martinou JC, Youle RJ. 2011. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 21:92-101. http://dx.doi.org/10.1016/j.devcel.2011.06.017.
47. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. 2005. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403. http://dx.doi.org/10.1016/j.molcel.2004.12.030.
48. Dai H, Smith A, Meng XW, Schneider PA, Pang YP, Kaufmann SH. 2011. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol 194:39-48. http://dx.doi.org/10.1083/jcb.201102027.
49. Yip KW, Reed JC. 2008. Bcl-2 family proteins and cancer. Oncogene 27:6398-6406. http://dx.doi.org/10.1038/onc.2008.307.
50. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208. http://dx.doi.org/10.1038/nm.3048.
51. Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H, Nowakowski GS, Dai H, Kaufmann SH. 2015. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochim Biophys Acta 1853:1658-1671. http://dx.doi.org/10.1016/j.bbamcr.2015.03.012.
52. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. 2013. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872-874. http://dx.doi.org/10.1182/blood-2013-05-501569.
53. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, Anderson MA, Rudersdorf N, Gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerickhouse R, Roberts AW. 2014. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. Abstr 8522. J Clin Oncol 32:5S.
54. + T cells after multiple doses of vorinostat. J Infect Dis 210:728-735. http://dx.doi.org/10.1093/infdis/jiu155.
55. +T cells from aviremic patients. PLoS Pathog 9:e1003834. http://dx.doi.org/10.1371/journal.ppat.1003834.
56. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD. 2013. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9:e1003174. http://dx.doi.org/10.1371/journal.ppat.1003174.
57. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, Lai J, McHugh HL, Hao H, Zhang H, Margolick JB, Gurer C, Murphy AJ, Valenzuela DM, Yancopoulos GD, Deeks SG, Strowig T, Kumar P, Siliciano JD, Salzberg SL, Flavell RA, Shan L, Siliciano RF. 2015. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517:381-385. http://dx.doi.org/10.1038/nature14053.
58. Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, Guo X, Shi W, Georgiev I, Zhou T, Chen X, O'Dell S, Todd JP, Kwong PD, Rao SS, Yang ZY, Koup RA, Mascola JR, Nabel GJ. 2015. Activation and lysis of human CD4 cells latently infected with HIV-1. NatCommun6:8447. http://dx.doi.org/10.1038/ncomms9447.
59. Pallikkuth S, Sharkey M, Babic DZ, Gupta S, Stone GW, Fischl MA, Stevenson M, Pahwa S. 2015. Peripheral T follicular helper cells are the major HIV reservoir within central memory CD4 T cells in peripheral blood from chronic HIV-infected individuals on cART. J Virol [Epub ahead of print].
60. Kennedy EM, Kornepati AV, Goldstein M, Bogerd HP, Poling BC, Whisnant AW, Kastan MB, Cullen BR. 2014. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. J Virol 88:11965-11972. http://dx.doi.org/10.1128/JVI.01879-14.
61. Clem RJ, Miller LK. 1994. Control of programmed cell death by the baculovirus genes p35 and iap. Mol Cell Biol 14:5212-5222. http://dx.doi.org/10.1128/MCB.14.8.5212.
62. Rubenwolf S, Schutt H, Nevels M, Wolf H, Dobner T. 1997. Structural analysis of the adenovirus type 5 E1B 55-kilodalton-E4orf6 protein complex. J Virol 71:1115-1123.
63. Clem RJ, Fechheimer M, Miller LK. 1991. Prevention of apoptosis by a baculovirus gene during infection of insect cells. Science 254:1388-1390. http://dx.doi.org/10.1126/science.1962198.
64. Altmann M, Hammerschmidt W. 2005. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3:e404. http://dx.doi.org/10.1371/journal.pbio.0030404.
65. Pilder S, Logan J, Shenk T. 1984. Deletion of the gene encoding the adenovirus 5 early region 1b 21,000-molecular-weight polypeptide leads to degradation of viral and host cell DNA. J Virol 52:664-671.
66. Lum JJ, Badley AD. 2003. Resistance to apoptosis: mechanism for the development of HIV reservoirs. Curr HIV Res 1:261-274. http://dx.doi.org/10.2174/1570162033485203.
67. Cummins NW, Badley AD. 2013. Antiapoptotic mechanisms of HIV: lessons and novel approaches to curing HIV. Cell Mol Life Sci 70:3355-3363. http://dx.doi.org/10.1007/s00018-012-1239-3.
68. + T lymphocytes: a potential mechanism for persistent viral production. J Biol Chem 288:7626-7644. http://dx.doi.org/10.1074/jbc.M112.408294.
69. Wolf D, Witte V, Laffert B, Blume K, Stromer E, Trapp S, d'Aloja P, Schurmann A, Baur AS. 2001. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce antiapoptotic signals. Nat Med 7:1217-1224. http://dx.doi.org/10.1038/nm1101-1217.
70. + T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence. J Immunol 165:6437-6446. http://dx.doi.org/10.4049/jimmunol.165.11.6437.
71. Chinnaiyan AM, Woffendin C, Dixit VM, Nabel GJ. 1997. The inhibition of proapoptotic ICE-like proteases enhances HIV replication. Nat Med 3:333-337. http://dx.doi.org/10.1038/nm0397-333.
72. + T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nat Protoc 9:2755-2770. http://dx.doi.org/10.1038/nprot.2014.188.
73. Widlak P, Garrard WT. 2005. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem 94:1078-1087. http://dx.doi.org/10.1002/jcb.20409.
74. Taylor RC, Cullen SP, Martin SJ. 2008. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9:231-241. http://dx.doi.org/10.1038/nrm2312.
75. + T cells infected with HIV. PLoS Pathog 9:e1003328. http://dx.doi.org/10.1371/journal.ppat.1003328.
76. Waterhouse N, Kumar S, Song Q, Strike P, Sparrow L, Dreyfuss G, Alnemri ES, Litwack G, Lavin M, Watters D. 1996. Heteronuclear ribonucleoproteins C1 and C2, components of the spliceosome, are specific targets of interleukin 1beta-converting enzyme-like proteases in apoptosis. J Biol Chem 271:29335-29341. http://dx.doi.org/10.1074/jbc.271.46.29335.
77. Luthi AU, Martin SJ. 2007. The CASBAH: a searchable database of caspase substrates. Cell Death Differ 14:641-650. http://dx.doi.org/10.1038/sj.cdd.4402103.
78. Kelve M, Truve E, Aaspollu A, Kuusksalu A, Dapper J, Perovic S, Muller WE, Schroder HC. 1994. Rapid reduction of mRNA coding for 2'-5'-oligoadenylate synthetase in rat pheochromocytoma PC12 cells during apoptosis. Cell Mol Biol 40:165-173.
79. Houge G, Robaye B, Eikhom TS, Golstein J, Mellgren G, Gjertsen BT, Lanotte M, Doskeland SO. 1995. Fine mapping of 28S rRNA sites specifically cleaved in cells undergoing apoptosis. Mol Cell Biol 15:2051-2062. http://dx.doi.org/10.1128/MCB.15.4.2051.
80. Samejima K, Earnshaw WC. 2005. Trashing the genome: the role of nucleases during apoptosis. Nat Rev Mol Cell Biol 6:677-688. http://dx.doi.org/10.1038/nrm1715.
81. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A. 1995. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIVand SIV-infected lymph nodes. Nat Med 1:129-134. http://dx.doi.org/10.1038/nm0295-129.
82. Roche. 2015. U.S. FDA grants breakthrough therapy designation for investigational Bcl-2 inhibitor venetoclax in 17p deletion relapsedrefractory chronic lymphocytic leukemia. Roche Molecular Systems, Branchburg, NJ. http://www.roche.com/investors/updates/inv-update-2015-05-07.htm.
83. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH. 2012. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4:132ra153. http://dx.doi.org/10.1126/scitranslmed.3003761.
84. Kumar S, Vij R, Kaufman JL, Mikhael J, Facon T, Moreau P, Amiot M, Alzate S, Morris LJ, Ross JA, Dunbar M, Zhu M, Agarwal SK, Leverson J, Enschede SH, Humerickhouse R, Touzeau C. 2015. Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM), abstr. J Clin Oncol. 33:8576.
85. Vandergeeten C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, Ramgopal M, Routy JP, Sekaly RP, Chomont N. 2013. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121:4321-4329. http://dx.doi.org/10.1182/blood-2012-11-465625.
86. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, Lai J, Blankson JN, Siliciano JD, Siliciano RF. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540-551. http://dx.doi.org/10.1016/j.cell.2013.09.020.
87. Karpel ME, Boutwell CL, Allen TM. 2015. BLT humanized mice as a small animal model of HIV infection. Curr Opin Virol 13:75-80. http://dx.doi.org/10.1016/j.coviro.2015.05.002.
88. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, Siliciano JD, Siliciano RF. 2015. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125:1901-1912. http://dx.doi.org/10.1172/JCI80142.
89. Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH. 2015. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood 125:658-667. http://dx.doi.org/10.1182/blood-2014-04-571786.
90. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
91. Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, Mahan A, Wang S, Kardar M, Yaari G, Walker LM, Simen BB, St John EP, Chan-Hui PY, Swiderek K, Kleinstein SH, Alter G, Seaman MS, Chakraborty AK, Koller D, Wilson IA, Church GM, Burton DR, Poignard P. 2013. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog 9:e1003754. http://dx.doi.org/10.1371/journal.ppat.1003754.
92. Natesampillai S, Nie Z, Cummins NW, Jochmans D, Bren GD, Angel JB, Badley AD. 2010. Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. PLoS Pathog 6:e1001213. http://dx.doi.org/10.1371/journal.ppat.1001213.
93. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK, Thiel E. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stemcell transplantation. N Engl J Med 360:692-698. http://dx.doi.org/10.1056/NEJMoa0802905.
94. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li J Z, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. 2014. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 161:319-327. http://dx.doi.org/10.7326/M14-1027.
95. Henrich TJ, Hanhauser E, Li JZ, Heisey A, Abramson JS, Hamdan A, Armand P, LaCasce AS, Kuritzkes DR. 2014. Impact of systemic cytotoxic chemotherapy for malignancies on HIV-1 reservoir persistence, abstr.
96. CROI Conference, Boston, MA. http://www.croiconference.org/sessions/impact-systemic-cytotoxic-chemotherapy-malignancies-hiv-1-reservoir-persistence-0.
97. Badley AD, Sainski A, Wightman F, Lewin SR. 2013. Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis 4:e718. http://dx.doi.org/10.1038/cddis.2013.248.